Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor
9.5.2023 09:00:00 EEST | Business Wire | Press release
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer. Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.
"Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, particularly in the field of brain metastasis by virtue of the high blood-brain barrier permeability of this asset,” stated Zack Cheng, M.D., Ph.D., Chairman, CEO and Co-Founder of Zion Pharma Limited. “Within five years, we have gone from company formation to first-in-human, to finding a partner in Roche, who has the resources and expertise to bring ZN-A-1041 to patients with few other therapeutic options,” Dr. Cheng continued.
Dr. Ding Zhou, Ph.D., CSO and Co-Founder of Zion Pharma Limited added, “We are pleased that Roche recognizes the potential of our asset for advancing the standard of care with regards to brain penetrable compounds in HER2-positive breast cancer.”
“We are excited to enter this partnership with Zion to further develop this innovative treatment option for people with HER2-positive breast cancer. This partnership builds on Roche’s legacy and expertise in the treatment of HER2-positive breast cancer and supports our pursuit of advancing science by combining external innovation with our in-house capabilities to address areas of high unmet patient needs,” said James Sabry, Global Head of Pharma Partnering.
After a transition period, Roche will be responsible for the further development, manufacturing, and commercialization of ZN-A-1041 globally. Zion will receive up to $70 million USD in upfront and near-term milestone payments pending achievement of certain milestone events. Zion will also be eligible for up to $610 million USD in additional payments following achievement of certain development, regulatory, and sales-based milestone events by ZN-A-1041, as well as tiered royalties on sales.
About ZN-A-1041
ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2). ZN-A-1041 was designed to be blood-brain-barrier-penetrant. The ongoing Phase 1 trial is being conducted at multiple sites in the U.S. and China. Additional details will be presented at the poster sessions during the American Society of Clinical Oncology Annual Meeting in June 2023.
About Zion Pharma Limited
Zion Pharma is a private, clinical stage biotech company focused on the development of novel, small molecule, anti-tumoral agents. Founded in 2018, the company’s research headquarters are in Suzhou with additional research operations in Shanghai. The company is applying an innovative drug discovery approach, capitalizing on its DMPK expertise, to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (ATM), Kirsten RAt Sarcoma (KRAS G12D) and SMARCA2 (BRM). Additional information about Zion Pharma is available at www.zionpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005468/en/
Contact information
For media and partnership inquiries:
J. Michael French
SVP, Corporate Development
michael.french@zionpharma.com
+1.703.338.1972
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ on Databricks to Accelerate AI Monetization17.6.2026 10:46:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse for Databricks, a new offering that brings together LTM’s AI ecosystem, BlueVerse™, with Databricks, the Data and AI company, to accelerate AI-driven data monetization. BlueVerse for Databricks is designed to help enterprises drive tangible business outcomes from data and AI investments by addressing critical challenges in the secure and efficient management of data and compute resources, while optimizing business processes and providing pre-built industry solutions to unlock greater value from AI initiatives. LTM BlueVerse helps companies reimagine core business processes such as procure-to-pay, order-to-cash, hire-to-retire, and marketing operations as AI-optimized workflows. It also enables organizations to accelerate time-to-value through pre-built, industry-specific solutions for Manufacturing, Banking, Financial Services, Insurance, Media & Entertainment, and Retail &
Wolters Kluwer Brings Libra AI Workflows into InView Legal for Belgian Legal Professionals17.6.2026 10:00:00 EEST | Press release
Wolters Kluwer Legal & Regulatory today announced the integration of Libra by Wolters Kluwer AI workflows in InView Legal (formerly known as Jura) in Belgium. This integration brings generative AI features directly into the research workflow of legal professionals and allows a seamless experience without switching between tools. The integration follows the launch of the Libra legal AI workspace in Belgium in February, combining AI with authoritative legal content from InView Legal and supporting lawyers across their full workflow, from research to analysis and document drafting. With the newly launched Libra add-in for InView Legal customers can use Libra’s AI functionalities for drafting, review and analysis in one unified environment, handling their work end-to-end. The solution reflects a broader market shift from standalone digital databases towards integrated, AI-powered workflows. “The integration of Libra into InView Legal marks the next step in the evolution of legal work: from
Zoya Technologies Launches Clinical AI Terminal Engineered to Operate Without Internet Connectivity17.6.2026 10:00:00 EEST | Press release
Almost every digital health system assumes the internet will be there. Zoya Technologies today launched the ZoyeMed 3.0 Resilience Edition, a clinical AI terminal engineered to deliver a complete medical episode without an internet connection at any stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617381037/en/ The ZoyeMed 3.0 Resilience Edition - a fully standalone clinical AI terminal engineered to operate without internet connectivity, integrating point-of-care diagnostics, examination tools, and on-device AI in a single 5-square-metre footprint (Photo: AETOSWire) Continuity of care is the first casualty of infrastructure disruption. Disasters, grid instability, and remote deployments routinely sever the connectivity that cloud-dependent systems require - when clinical capacity is most needed. The Resilience Edition is a fully standalone configuration of ZoyeMed 3.0. The complete Longitudinal Multimodal Model and
Owl Labs Launches Owl 360 Services, Bringing Enterprise Grade Intelligence to Hybrid Meetings17.6.2026 10:00:00 EEST | Press release
Owl Labs, the leader in 360-degree AI-powered video conferencing and hybrid collaboration technology, today announced Owl 360 Services, its first subscription service built to meet the needs of IT administrators. As organisations look to support hybrid work with deeper video enablement across more spaces, Owl 360 Services delivers three subscription tiers, offering dedicated support, centralised device management, proactive insights, and warranty coverage scaled to the size and complexity of the deployment. From launch, every Owl Labs device worldwide, whether newly purchased or already owned, is enrolled in the Core tier at no additional cost, giving all customers built-in analytics from the start. The Enhanced tier, available for direct purchase globally from this summer, adds advanced analytics, dashboards, meeting record history, and API integrations. A premium Enterprise tier, offered exclusively through authorised Owl Labs channel partners, is available now in North America, with
Cognite Launches Novel Integrated Supply Chain Offering to Deliver Unprecedented Business Value with AI17.6.2026 09:00:00 EEST | Press release
Cognite, a global leader in Industrial AI, today announced the launch of its Integrated Supply Chain offering. This new solution area extends the Cognite AI and Data Platform beyond the plant, equipping industrial teams with real-time visibility, insights, and cross-functional context to finally bridge the long-standing data gap between production and supply chain operations. Unifying these siloed teams empowers organizations to respond faster and smarter to internal or external disruptions, execute adaptive pivots, and better protect margins. The divide between production and supply chain operations has increased over time, as competing KPIs, organizational initiatives, and specialized software further fragment decision-making processes. As a result, any operational disruption can force costly, reactive firefighting; supply chain penalties; and production stalls, where slow decision making can cost up to 5% of top-line revenue or over $50M annually for a $1B organization[1]. “Right no
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom